Clinical
RSSArticles
-
Clinical Features and Consequences of Inclusion Body Myositis
Inclusion body myositis, while poorly understood regarding cause, is clearly responsive to physical exercise, and patients should be encouraged to maintain robust physical activity.
-
Medication for Acute Low Back — A Randomized Clinical Trial
In a trial comparing naproxyn alone to combinations with cyclobenzaprine or oxycodone/acetaminophen in patients with acute low back pain, there was no difference in outcome after 1 week.
-
No More Bacon? Carcinogenicity of Meat
A review of published research by the World Health Organization concludes that processed meats are probably carcinogenic.
-
The Removal of Dietary Fructose Improves Pediatric Health
In 43 children with obesity and metabolic syndrome, 9 days of dietary sugar reduction (isocaloric with starch substitution) improved numerous metabolic parameters and led to more than 2 pounds of weight loss.
-
High-intensity Intermittent Training for Type 2 Diabetes Mellitus
High-intensity intermittent training improves cardiac structure and function in addition to reducing liver and visceral fat mass among non-insulin dependent type 2 diabetics.
-
Mediterranean Diet Increases Brain Volume
Higher adherence to the Mediterranean diet led to measurable increases in brain volume in a multi-ethnic sampling of older adults.
-
Prevention of Relapse in Depression: Antidepressants or Mindfulness-based Cognitive Therapy?
Maintenance antidepressants or mindfulness-based cognitive therapy aimed at tapering or discontinuing antidepressants are both effective interventions for prevention of recurrent depression.
-
Infectious Disease Alert Updates
Borrelia Miyamotoi in My Backyard! Who Knew?
Fecal Microbiota Transplantation — Patients Need No Convincing
-
Malaria in Pregnancy — Good News, Bad News, and Opportunity
With waning natural immunity against malaria, women face increased adverse consequences of malaria infection during pregnancy. As malaria is being conquered, good clinical care of vulnerable individuals is still essential.
-
Ceftazidime-avibactam — Formulary Considerations
Ceftazidime-avibactam is a new beta-lactam/beta-lactamase inhibitor combination approved for the treatment of complicated intra-abdominal infections in combination with metronidazole, and complicated urinary tract infections, including pyelonephritis in patients with limited alternative treatment options.